Investors Look to Capitalize on the Budding Green Revolution
Lithium is the uncontested fuel of the green energy revolution. One little-known small-cap lithium mining company in a renowned South American location has started attracting interest from opportunity-minded investors.
Discover this company's HUGE lithium potential
Jeff Fairman, insider at Vaxcyte

Jeff Fairman Insider Information

VP of Vaxcyte
Jeff has over 20 years of experience in the biotech arena having led the research at multiple platform companies that he co-founded resulting in multiple clinical candidates and approved vaccines and immunotherapeutics. Prior to Vaxcyte, Jeff was the founder and Vice President of Research at Juvaris BioTherapeutics, whose immunotherapeutic & vaccine adjuvant platform yielded multiple animal health products launched by its alliance partner Bayer HealthCare, including Zelnate® and Victrio®. While at Juvaris, Jeff was the recipient of major grant funding from multiple sources, including NIH and NCI, supporting substantial pre-clinical programs and multiple clinical studies. He was responsible for research activities resulting in multiple clinical candidates and the approved animal health products. Prior to Juvaris, Jeff was the Director of Pharmacogenomics at Clingenix and Senior Scientist at Valentis. Dr. Fairman has a Ph.D. in Chemistry and his postdoctoral training was in the genetics of leukemia at MD Anderson Cancer Center. Jeff enjoys spending time with his wife and daughter and has put his amateur taekwondo career on hold, for the time being, to be courtside rooting for his daughter’s school and club volleyball teams.

What is Jeff Fairman's net worth?

The estimated net worth of Jeff Fairman is at least $8.21 million as of August 4th, 2022. Dr. Fairman owns 311,227 shares of Vaxcyte stock worth more than $8,210,168 as of August 11th. This net worth estimate does not reflect any other assets that Dr. Fairman may own. Learn More about Jeff Fairman's net worth.

How old is Jeff Fairman?

Dr. Fairman is currently 58 years old. There are 7 older executives and no younger executives at Vaxcyte. The oldest executive at Vaxcyte is Mr. Paul W. Sauer M.B.A., MBA, Sr. VP of Process Devel. & Manufacturing, who is 61 years old. Learn More on Jeff Fairman's age.

How do I contact Jeff Fairman?

The corporate mailing address for Dr. Fairman and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111. Learn More on Jeff Fairman's contact information.

Has Jeff Fairman been buying or selling shares of Vaxcyte?

During the last quarter, Jeff Fairman has sold $255,000.00 in shares of Vaxcyte stock. Most recently, Jeff Fairman sold 10,000 shares of the business's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $25.50, for a transaction totalling $255,000.00. Following the completion of the sale, the vice president now directly owns 311,227 shares of the company's stock, valued at $7,936,288.50. Learn More on Jeff Fairman's trading history.

Who are Vaxcyte's active insiders?

Vaxcyte's insider roster includes Jeff Fairman (VP), Andrew Guggenhime (CFO), Grant Pickering (CEO), Paul Sauer (SVP), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.

Are insiders buying or selling shares of Vaxcyte?

In the last year, insiders at the sold shares 42 times. They sold a total of 263,513 shares worth more than $6,332,518.39. The most recent insider tranaction occured on August, 4th when VP Jeff Fairman sold 10,000 shares worth more than $255,000.00. Insiders at Vaxcyte own 13.7 % of the company. Learn More about insider trades at Vaxcyte.

Information on this page was last updated on 8/4/2022.

Jeff Fairman Insider Trading History at Vaxcyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/4/2022Sell10,000$25.50$255,000.00311,227View SEC Filing Icon  
5/20/2022Sell4,112$25.50$104,856.00321,227View SEC Filing Icon  
5/5/2022Sell888$25.80$22,910.40325,339View SEC Filing Icon  
4/5/2022Sell5,000$25.59$127,950.0016,629View SEC Filing Icon  
3/11/2022Sell10,000$25.50$255,000.00View SEC Filing Icon  
12/27/2021Sell4,750$23.60$112,100.00View SEC Filing Icon  
12/16/2021Sell4,619$22.50$103,927.50View SEC Filing Icon  
12/9/2021Sell131$22.50$2,947.50View SEC Filing Icon  
10/26/2021Sell4,750$22.69$107,777.50View SEC Filing Icon  
9/27/2021Sell4,750$26.17$124,307.50View SEC Filing Icon  
8/26/2021Sell4,750$25.38$120,555.009,894View SEC Filing Icon  
7/26/2021Sell4,750$22.70$107,825.009,894View SEC Filing Icon  
6/28/2021Sell4,750$24.37$115,757.509,894View SEC Filing Icon  
6/7/2021Sell9,500$22.50$213,750.00View SEC Filing Icon  
3/26/2021Sell4,750$23.88$113,430.006,158View SEC Filing Icon  
2/26/2021Sell4,750$23.93$113,667.506,158View SEC Filing Icon  
1/26/2021Sell4,750$25.27$120,032.506,158View SEC Filing Icon  
See Full Table

Jeff Fairman Buying and Selling Activity at Vaxcyte

This chart shows Jeff Fairman's buying and selling at Vaxcyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaxcyte Company Overview

Vaxcyte logo
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $25.72
Low: $25.32
High: $26.61

50 Day Range

MA: $22.37
Low: $17.68
High: $26.38

2 Week Range

Now: $25.72
Low: $16.78
High: $27.44

Volume

3,560 shs

Average Volume

276,270 shs

Market Capitalization

$1.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52
Investors Look to Capitalize on the Budding Green Revolution
Lithium is the uncontested fuel of the green energy revolution. One little-known small-cap lithium mining company in a renowned South American location has started attracting interest from opportunity-minded investors.
Discover this company's HUGE lithium potential